-
1 Comment
Hybio Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 12.2% below its 200 day moving average.
From a valuation standpoint, the stock is 31.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.6.
Hybio Pharmaceutical Co., Ltd's total revenue rose by 133.2% to $247M since the same quarter in the previous year.
Its net income has increased by 105.6% to $9M since the same quarter in the previous year.
Finally, its free cash flow grew by 84.0% to $-53M since the same quarter in the previous year.
Based on the above factors, Hybio Pharmaceutical Co., Ltd gets an overall score of 4/5.
| Industry | Drug Manufacturers - Specialty & Generic |
|---|---|
| Exchange | SHE |
| CurrencyCode | CNY |
| ISIN | CNE1000011T7 |
| Sector | Healthcare |
| Market Cap | 18B |
|---|---|
| PE Ratio | None |
| Target Price | 15.05 |
| Beta | 0.78 |
| Dividend Yield | None |
Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as disposable injectable pens; and peptide active pharmaceutical ingredients (API) comprising polypeptides, small molecules and nucleic acids, and intermediates for endocrine, nutritional, and metabolic diseases; digestive system diseases; neoplasms; nervous system diseases; pregnancy, childbirth, and puerperium; musculoskeletal system and connective tissue diseases; infectious and parasitic diseases; circulatory system diseases; blood and hematopoietic organ diseases; and genitourinary system diseases, as well as factors influencing health status. It also provides contract research, development, and manufacturing organization (CRDMO) services for peptide APIs, peptide formulations, oligonucleotide drugs, and pharmaceutical intermediates. In addition, the company engages in the provision of property services. Hybio Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Wuhan, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300199.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
